ECSP099716A - Extrudidos con enmascaramiento del sabor mejorado - Google Patents

Extrudidos con enmascaramiento del sabor mejorado

Info

Publication number
ECSP099716A
ECSP099716A EC2009009716A ECSP099716A ECSP099716A EC SP099716 A ECSP099716 A EC SP099716A EC 2009009716 A EC2009009716 A EC 2009009716A EC SP099716 A ECSP099716 A EC SP099716A EC SP099716 A ECSP099716 A EC SP099716A
Authority
EC
Ecuador
Prior art keywords
extruded
improved flavor
flavor mask
extrudates
mask
Prior art date
Application number
EC2009009716A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Hans-Juergen Hamann
Peter Kleinebudde
Andrea Michalk
Claudia Reitz
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP099716A publication Critical patent/ECSP099716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Fats And Perfumes (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

La invención se refiere a extrudidos que contienen una o varias sustancia(s) farmacéuticamente activa(s), en donde los extrudidos presentan un diámetro de hebra de 0,5 mm o inferior, así como al uso de estos extrudidos para la preparación de fármacos.
EC2009009716A 2007-06-08 2009-11-06 Extrudidos con enmascaramiento del sabor mejorado ECSP099716A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007026550A DE102007026550A1 (de) 2007-06-08 2007-06-08 Extrudate mit verbesserter Geschmacksmaskierung

Publications (1)

Publication Number Publication Date
ECSP099716A true ECSP099716A (es) 2009-12-28

Family

ID=39790368

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009716A ECSP099716A (es) 2007-06-08 2009-11-06 Extrudidos con enmascaramiento del sabor mejorado

Country Status (36)

Country Link
US (1) US20100197571A1 (es)
EP (1) EP2170272B1 (es)
JP (2) JP5775302B2 (es)
KR (2) KR101600800B1 (es)
CN (1) CN101677946A (es)
AR (1) AR066914A1 (es)
AU (1) AU2008258887B2 (es)
BR (1) BRPI0812432B8 (es)
CA (1) CA2689486C (es)
CL (1) CL2008001575A1 (es)
CO (1) CO6260054A2 (es)
CR (1) CR11096A (es)
DE (1) DE102007026550A1 (es)
DK (1) DK2170272T3 (es)
DO (1) DOP2009000255A (es)
EC (1) ECSP099716A (es)
ES (1) ES2625138T3 (es)
GT (1) GT200900287A (es)
HR (1) HRP20170747T1 (es)
HU (1) HUE032719T2 (es)
IL (1) IL201708A0 (es)
MX (1) MX2009011999A (es)
MY (1) MY157780A (es)
NI (1) NI200900198A (es)
NZ (1) NZ581670A (es)
PE (1) PE20090761A1 (es)
PL (1) PL2170272T3 (es)
PT (1) PT2170272T (es)
RU (2) RU2009148576A (es)
SI (1) SI2170272T1 (es)
SV (1) SV2009003403A (es)
TW (1) TWI483738B (es)
UA (1) UA97401C2 (es)
UY (1) UY31117A1 (es)
WO (1) WO2008148484A1 (es)
ZA (1) ZA200908647B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172191A1 (en) * 2008-10-01 2010-04-07 Heinrich-Heine-Universität Düsseldorf Lipid pellets with enhanced taste-masking
AU2009321822B2 (en) * 2008-12-05 2015-04-16 Bayer Intellectual Property Gmbh Extrudate having spicular active substances
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
HU231017B1 (hu) 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
EP3181317A1 (de) * 2015-12-18 2017-06-21 LANXESS Deutschland GmbH Verfahren zur herstellung von feststoffpartikeln
CN108888598A (zh) * 2018-08-01 2018-11-27 江西成必信生物科技有限公司 口服易吸收的布他磷及其制备方法
CN111529499B (zh) * 2020-06-11 2021-09-17 华中农业大学 一种兽用恩诺沙星风味片剂及其制备方法
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
JPS61240963A (ja) * 1985-04-18 1986-10-27 ユニチカ株式会社 創傷被覆保護材
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
JP2579610B2 (ja) * 1990-09-28 1997-02-05 鳥取大学長 生体内充填剤
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AUPM969994A0 (en) * 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
JP3418274B2 (ja) * 1995-06-05 2003-06-16 日本化薬株式会社 口腔内感触の良好な錠剤
US6323213B1 (en) 1996-02-23 2001-11-27 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
DE19628776A1 (de) 1996-07-17 1998-01-22 Bayer Ag Oral applizierbare Granulate von Hexahydropyrazinderivaten
AU707949C (en) * 1996-07-30 2006-01-19 Merial, Inc. Anthelmintic formulations
FR2753904B1 (fr) 1996-10-01 1998-10-30 Gattefosse Ets Sa Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication
CA2227314A1 (en) 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
KR20010072151A (ko) * 1998-07-31 2001-07-31 히구치 다츠오 맛이 개선된 약제학적 조성물
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
US6500463B1 (en) * 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
US20020122824A1 (en) * 2001-01-24 2002-09-05 Francisco Cabrera Solid phase dispersion of quinolone-or naphthyridonecarboxylic acids
US6716448B2 (en) * 2001-10-05 2004-04-06 Rubicon Scientific Llc Domesticated household pet food including maintenance amounts of ivermectin
CN1589155B (zh) 2001-10-05 2010-05-26 鲁比康科学有限公司 含有活性物质的动物饲料和使用方法
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
PL377351A1 (pl) * 2002-12-13 2006-01-23 Cilag Ag Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
JP4210615B2 (ja) * 2004-03-26 2009-01-21 エスエス製薬株式会社 不快な味がマスキングされた製剤
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
US8236349B2 (en) * 2004-04-12 2012-08-07 Bend Research Inc. Taste-masked drugs in rupturing multiparticulates
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
JP4731941B2 (ja) * 2005-02-14 2011-07-27 大正薬品工業株式会社 経口製剤用粒子
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins

Also Published As

Publication number Publication date
UA97401C2 (ru) 2012-02-10
CO6260054A2 (es) 2011-03-22
UY31117A1 (es) 2009-01-30
NI200900198A (es) 2011-12-14
EP2170272A1 (de) 2010-04-07
DOP2009000255A (es) 2009-12-15
BRPI0812432B1 (pt) 2019-04-16
BRPI0812432A2 (pt) 2014-12-02
CL2008001575A1 (es) 2008-12-19
SI2170272T1 (sl) 2017-06-30
SV2009003403A (es) 2010-05-17
US20100197571A1 (en) 2010-08-05
TWI483738B (zh) 2015-05-11
PE20090761A1 (es) 2009-07-23
PT2170272T (pt) 2017-05-24
WO2008148484A1 (de) 2008-12-11
RU2014124814A (ru) 2015-12-27
AU2008258887B2 (en) 2014-06-26
MY157780A (en) 2016-07-29
CR11096A (es) 2010-06-28
MX2009011999A (es) 2009-11-19
TW200914051A (en) 2009-04-01
ES2625138T3 (es) 2017-07-18
KR20100017385A (ko) 2010-02-16
JP2014114310A (ja) 2014-06-26
CA2689486C (en) 2016-03-22
KR20150110825A (ko) 2015-10-02
CN101677946A (zh) 2010-03-24
DK2170272T3 (en) 2017-06-06
BRPI0812432B8 (pt) 2021-05-25
NZ581670A (en) 2012-07-27
RU2009148576A (ru) 2011-07-20
PL2170272T3 (pl) 2017-08-31
DE102007026550A1 (de) 2008-12-11
AR066914A1 (es) 2009-09-23
CA2689486A1 (en) 2008-12-11
AU2008258887A1 (en) 2008-12-11
HRP20170747T1 (hr) 2017-07-28
KR101600800B1 (ko) 2016-03-08
ZA200908647B (en) 2011-02-23
GT200900287A (es) 2011-11-09
HUE032719T2 (en) 2017-10-30
IL201708A0 (en) 2010-05-31
JP5775302B2 (ja) 2015-09-09
JP2010529059A (ja) 2010-08-26
EP2170272B1 (de) 2017-03-29

Similar Documents

Publication Publication Date Title
ECSP099716A (es) Extrudidos con enmascaramiento del sabor mejorado
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
DOP2006000170A (es) Nuevos derivados de espirocromanona
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CY1122416T1 (el) Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
PE20142371A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CR20120296A (es) Nuevos compuestos de espiropiperidina
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2008002247A1 (es) Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
CL2013003111A1 (es) Metodo para la preparacion de una composicion farmaceutica que contiene un transportador de oxigeno purificado y termicamente estable, que contiene el transportador de oxigeno hemoglobina, donde la hemoglobina incluye a hemoglobina polimerica entrecruzada.
CO6410291A2 (es) 3-amino-2-mercaptoquinolina sustituidacomo modulador de kcnq2/3
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
CR20160042A (es) ANTAGONISTAS DE V1a PARA TRATAR TRASTORNOS DEL SUEÑO POR CAMBIO DE FASE
UY29517A1 (es) Nueva clase de 4-lactama benzonitrilos, composiciones farmacéuticas que los contienen y aplicaciones
DOP2007000121A (es) Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso
CL2008003780A1 (es) Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras.
UY31522A1 (es) Nanoparticulas con superficie modificada